Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.[3]
Medical use
The medical use is indicated for the control of absence seizures that are refractory to other drugs.[2]
References
- Pfizer AG. Petinutin (Mésuximide) Official Pfizer AG Website, 2005, retrieved August 21, 2006^
- Pfizer Inc. Celontin (methsuximide capsules, USP) Official Pfizer Inc. Website, 2008, retrieved November 21, 2014^
- Plasma concentrations of phensuximide, methsuximide, and their metabolites in relation to clinical efficacy Neurology, November 1979